Sengenics, an immuno-diagnostics and therapeutics biotechnology company, today announced the launch of the iTAP Technology Access Program for its unique functional protein array platform, Immunome. The announcement was made at the opening of the 15th Human Proteome Organization (HUPO) World Congress in Taipei, Taiwan.
Through the program, iTAP partners will be granted a license to fully leverage the Immunome technology, with open rights to use, commercialise and patent discoveries. In addition, full access will be given to the Sengenics R&D team coupled with on-site support and code-level access to data analysis pipelines. Licensees will also be eligible for a 70% subsidy on the cost of Immunome arrays, associated reagents, new assay development and custom protein manufacturing.
The iTAP program is primarily targeted at large pharmaceutical and biotechnology companies to facilitate discovery in a deep collaborative fashion to fully leverage the Immunome technology for antibody-based drug discovery, antibody specificity screening and on-array enzyme assays. As all Immunome proteins are correctly folded, functional and contain both conformational and linear epitopes, the probability of meaningful and robust results is greatly increased.
Professor Jonathan Blackburn, Chief Scientific Advisor of Sengenics, said, â€œWe aim to practice this new concept of open innovation, by leveraging one anotherâ€™s products, technologies and intellectual property. I believe iTAP will provide the means for collaborators to rapidly enhance and grow their biomarker, drug and diagnostic discovery portfolios by tapping into the exciting new potential of antibody-based therapeutics, precision medicine and patient stratification using Immunome.â€ He went on to state that 2016 has already seen acceleration of the development of the Immunome protein array technology into new areas that had not been previously considered, largely as a consequence of new collaborations with pharmaceutical companies and leading academic institutions.
In the past 12 months, Sengenics has partnered with 27 new organizations ranging from top pharmaceutical companies to academic institutions spanning the United States, Europe and Asia.
Professor Blackburn will be presenting a lecture at the HUPO Congress entitled “Quantitative Activity-Based Profiling of Kinase Inhibitor Binding and Selectivity on Protein Microarrays Containing >300 Human Protein Kinases.”
Sengenics is an immuno-diagnostics and therapeutics biotechnology company. Our key focus is leveraging our core patented Immunome protein array technology which was spun out from research that was commercialised as a joint collaboration between the University of Oxford and the University of Cambridge. The four key applications of Immunome are; Discovery of antibody-based therapeutics, discovery of autoantibody biomarkers, on-array kinase and DNA binding assays, and antibody specificity assays.
Related news link: www.prweb.com/releases/2016/09/prweb13690886.htm